US · Healthcare · Biotechnology
EPS came in at 1.21 against a street estimate of 1.44 — a miss of 16.0%.
Analysts rate Alnylam Pharmaceuticals Inc a buy (22 buy, 8 hold, 0 sell out of 30) with an average price target of $386.29.
| Fund | Stake |
|---|---|
| FMR Inc | 10.90% |
| Capital World Investors | 8.07% |
| BlackRock Inc | 7.81% |
| Capital Research Global Investors | 7.08% |
| Vanguard Portfolio Management, LLC | 4.85% |
| JPMorgan Chase & Co | 4.73% |
| Vanguard Capital Management, LLC | 4.44% |
| T. Rowe Price Investment Management,Inc. | 3.88% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-30 |
| Results announced · Q3 2026 | 2026-07-30 |
| Board / officer change · Q2 2026 | 2026-05-27 |
| Quarterly report · Q1 2026 | 2026-04-30 |
| Results announced · Q2 2026 | 2026-04-30 |
| Proxy statement · Q2 2026 | 2026-04-06 |
| Board / officer change · Q1 2026 | 2026-03-04 |
| Annual report FY2025 | 2026-02-12 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2025 preliminary revenues and 2026 combined product revenue guidance provided Alnylam Pharmaceuticals announced strong 2025 preliminary results and a new five-year strategic plan called 'Alnylam 2030' on January 11, 2026. The company reported full year 2025 net produc | 2026-01-12 |
| Repurchase of convertible senior notes for approximately $34.4 million Alnylam Pharmaceuticals announced on December 10, 2025, that it repurchased approximately $34.4 million in principal amount of its 1.00% convertible senior notes due 2027 for a total cash co | 2025-12-11 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Alnylam Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.